![Madiha Derouazi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Madiha Derouazi
Grundare på
Amal Therapeutics SA
Profil
Madiha Derouazi is the founder of Amal Therapeutics SA, founded in 2012, serving as Chief Executive Officer & Director since its founding.
The current job is Chief Executive Officer at Switchkine SA starting in 2025.
Former jobs include Chief Executive Officer at Speransa Therapeutics GmbH and Chief Scientific Officer at AC Immune SA. Education includes graduate studies at the Technical University of Berlin and a doctorate from the Swiss Federal Institute of Technology.
Aktiva positioner av Madiha Derouazi
| Företag | Position | Start |
|---|---|---|
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Operates a proprietary cell penetrating peptide platform which develops therapeutic vaccines in oncology | Grundare | 2012-09-03 |
Tidigare kända positioner av Madiha Derouazi
| Företag | Position | Slut |
|---|---|---|
| AC IMMUNE SA | Teknisk/Vetenskaplig/F&U Direktör | - |
Madiha Derouazis utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
6
Första gradens relationer
4
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
AC Immune SA
 AC Immune SA Pharmaceuticals: MajorHealth Technology Manufactures precision medicines for neurodegenerative diseases | Health Technology |
Technical University of Berlin
 Technical University of Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swiss Federal Institute of Technology
 Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Operates a proprietary cell penetrating peptide platform which develops therapeutic vaccines in oncology | Health Technology |
